FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004800014> ?p ?o ?g. }

• W2004800014 endingPage "556" @default.
• W2004800014 startingPage "547" @default.
• W2004800014 abstract "OBJECT Glioblastoma is a rapidly infiltrating tumor that consistently rematerializes despite various forms of aggressive treatment. Brain tumors are commonly treated with alkylating drugs, such as lomustine, which are chemotherapeutic agents. Use of these drugs, however, is associated with serious side effects. To reduce the side effects, one approach is to combine lower doses of chemotherapeutic drugs with other nontoxic anticancer agents. In this study, using glioblastoma cell lines, the authors investigated the anticancer effects of lomustine, alone and in combination with docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid normally abundant in the brain and known for its anticancer potential. METHODS Cells were cultured from 3 human-derived tumor cell lines (U87-MG, DB029, and MHBT161) and supplemented with either DHA or lomustine to determine the growth inhibitory potential using WST-1, a mitochondrial functional indicator. Human-derived cerebral cortex microvascular endothelial cells served as a normal phenotypic control. Cellular incorporation of DHA was analyzed by gas chromatography. Using flow cytometric analysis, the DHA and/or lomustine effect on induction of apoptosis and/or necrosis was quantified; subsequently, the DHA and lomustine effect on cell cycle progression was also assessed. Western blot analysis confirmed the role of downstream cellular targets. RESULTS U87-MG growth was inhibited with the supplementation of either DHA (ED 50 68.3 μM) or lomustine (ED 50 68.1 μM); however, growth inhibition was enhanced when U87-MG cells were administered equimolar doses of each compound, resulting in nearly total growth inhibition at 50 μM. Gas chromatography analysis of the fatty acid profile in DHA-supplemented U87-MG cells resulted in a linear dose-dependent increase in DHA incorporation (< 60 μM). The combination of DHA and lomustine potently induced U87-MG apoptosis and necrosis as indicated by flow cytometric analysis. Activation of caspase-3 and poly (ADP-ribose) polymerase (PARP) was evident in lomustine-treated U87-MG cells, although this activation did not appear to be dependent on DHA supplementation. Additionally, lomustine-treated cells' growth arrested in the G 2 /M cell cycle stage, regardless of the presence of DHA. Similar to the U87-MG observations, the combination of DHA and lomustine resulted in growth inhibition of 2 additional human-derived glioblastoma cell lines, DB029 and MHBT161. Importantly, in primary human-derived cerebral cortex endothelial cells, this combination was only growth inhibitory (40.8%) at the highest dose screened (100 μM), which indicates a certain degree of selectivity toward glioblastoma. CONCLUSIONS Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas." @default.
• W2004800014 created "2016-06-24" @default.
• W2004800014 creator A5011655514 @default.
• W2004800014 creator A5012639427 @default.
• W2004800014 creator A5016565900 @default.
• W2004800014 creator A5023265907 @default.
• W2004800014 creator A5077643720 @default.
• W2004800014 creator A5084350144 @default.
• W2004800014 creator A5089265440 @default.
• W2004800014 date "2015-03-01" @default.
• W2004800014 modified "2023-09-27" @default.
• W2004800014 title "Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines" @default.
• W2004800014 cites W1527114747 @default.
• W2004800014 cites W1961127914 @default.
• W2004800014 cites W1963866419 @default.
• W2004800014 cites W1975504666 @default.
• W2004800014 cites W1977273204 @default.
• W2004800014 cites W1982111518 @default.
• W2004800014 cites W1983118000 @default.
• W2004800014 cites W1993721507 @default.
• W2004800014 cites W2007108239 @default.
• W2004800014 cites W2007928899 @default.
• W2004800014 cites W2015213028 @default.
• W2004800014 cites W2061327286 @default.
• W2004800014 cites W2061342330 @default.
• W2004800014 cites W2063863812 @default.
• W2004800014 cites W2067966290 @default.
• W2004800014 cites W2070774628 @default.
• W2004800014 cites W2076048188 @default.
• W2004800014 cites W2078549792 @default.
• W2004800014 cites W2078815354 @default.
• W2004800014 cites W2096287682 @default.
• W2004800014 cites W2101200891 @default.
• W2004800014 cites W2102746728 @default.
• W2004800014 cites W2103987247 @default.
• W2004800014 cites W2114571023 @default.
• W2004800014 cites W2115604279 @default.
• W2004800014 cites W2123808042 @default.
• W2004800014 cites W2129648100 @default.
• W2004800014 cites W2130015179 @default.
• W2004800014 cites W2130511906 @default.
• W2004800014 cites W2134522229 @default.
• W2004800014 cites W2160959204 @default.
• W2004800014 cites W2168526937 @default.
• W2004800014 cites W2169869816 @default.
• W2004800014 cites W2170650084 @default.
• W2004800014 cites W2211467290 @default.
• W2004800014 cites W2290370864 @default.
• W2004800014 cites W2314104762 @default.
• W2004800014 cites W2318325971 @default.
• W2004800014 doi "https://doi.org/10.3171/2014.10.jns14759" @default.
• W2004800014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25526274" @default.
• W2004800014 hasPublicationYear "2015" @default.
• W2004800014 type Work @default.
• W2004800014 sameAs 2004800014 @default.
• W2004800014 citedByCount "18" @default.
• W2004800014 countsByYear W20048000142016 @default.
• W2004800014 countsByYear W20048000142017 @default.
• W2004800014 countsByYear W20048000142018 @default.
• W2004800014 countsByYear W20048000142020 @default.
• W2004800014 countsByYear W20048000142021 @default.
• W2004800014 countsByYear W20048000142022 @default.
• W2004800014 countsByYear W20048000142023 @default.
• W2004800014 crossrefType "journal-article" @default.
• W2004800014 hasAuthorship W2004800014A5011655514 @default.
• W2004800014 hasAuthorship W2004800014A5012639427 @default.
• W2004800014 hasAuthorship W2004800014A5016565900 @default.
• W2004800014 hasAuthorship W2004800014A5023265907 @default.
• W2004800014 hasAuthorship W2004800014A5077643720 @default.
• W2004800014 hasAuthorship W2004800014A5084350144 @default.
• W2004800014 hasAuthorship W2004800014A5089265440 @default.
• W2004800014 hasBestOaLocation W20048000141 @default.
• W2004800014 hasConcept C126322002 @default.
• W2004800014 hasConcept C128473837 @default.
• W2004800014 hasConcept C190283241 @default.
• W2004800014 hasConcept C19038510 @default.
• W2004800014 hasConcept C2776694085 @default.
• W2004800014 hasConcept C2776755627 @default.
• W2004800014 hasConcept C2777171753 @default.
• W2004800014 hasConcept C2778227246 @default.
• W2004800014 hasConcept C2779429289 @default.
• W2004800014 hasConcept C2779434656 @default.
• W2004800014 hasConcept C502942594 @default.
• W2004800014 hasConcept C543025807 @default.
• W2004800014 hasConcept C54355233 @default.
• W2004800014 hasConcept C55493867 @default.
• W2004800014 hasConcept C62112901 @default.
• W2004800014 hasConcept C71924100 @default.
• W2004800014 hasConcept C81885089 @default.
• W2004800014 hasConcept C86803240 @default.
• W2004800014 hasConcept C98274493 @default.
• W2004800014 hasConceptScore W2004800014C126322002 @default.
• W2004800014 hasConceptScore W2004800014C128473837 @default.
• W2004800014 hasConceptScore W2004800014C190283241 @default.
• W2004800014 hasConceptScore W2004800014C19038510 @default.
• W2004800014 hasConceptScore W2004800014C2776694085 @default.
• W2004800014 hasConceptScore W2004800014C2776755627 @default.
• W2004800014 hasConceptScore W2004800014C2777171753 @default.

• next